000 | 03082nam a22003858i 4500 | ||
---|---|---|---|
001 | zzv350 b1853231 | ||
003 | DLC | ||
005 | 20231102192126.0 | ||
008 | 220523t20232023cau b 001 0 eng | ||
010 | _a2022023732 | ||
020 | _a0520388712 (paperback) | ||
020 | _a9780520388710 (paperback) | ||
040 |
_aCU-S/DLC _beng _erda _cDLC _dMiTN |
||
050 | 4 |
_aHD9666.4 _b.R58 2023 |
|
100 | 1 |
_aRoy, Victor, _d1986- |
|
245 | 1 | 0 |
_aCapitalizing a cure : _bhow finance controls the price and value of medicines / _cVictor Roy. |
263 | _a2301. | ||
264 | 1 |
_aOakland, California : _bUniversity of California Press, _c[2023] |
|
264 | 4 | _cA2023. | |
300 | _apages cm. | ||
336 |
_atext _btxt _2rdacontent. |
||
337 |
_aunmediated _bn _2rdamedia. |
||
338 |
_avolume _bnc _2rdacarrier. |
||
504 | _aIncludes bibliographical references and index. | ||
505 | 0 | _aPreface : pandemics, Wall Street, and the value playbook -- Introduction : the politics of drug pricing and the value of a cure -- Capitalizing science : public knowledge into pharmaceutical assets -- Capitalizing drugs : shareholder power and the cannibalizing company -- Capitalizing health : the struggle over value and treatment access -- From financialization to public purpose for health -- Conclusion : reckoning with pharmaceutical value in crisis times. | |
520 |
_a"Capitalizing a Cure takes us into the struggle over accessing a medical breakthrough to investigate the power of finance over business, biomedicine, and public health. When sofosbuvir-based medicines launched in 2013, they promised a cure for millions ofpatients worldwide with hepatitis C. But their sticker shock-the drug was dubbed "the $1,000-a-day pill"-intensified a global debate over the pricing of new medicines. Weaving extensive historical research with insights from political economy and scienceand technology studies, Victor Roy demystifies an oft-missed dynamic in this debate: the reach of financialized capitalism into how medicines are made, priced, and valued. His account travels between public and private labs, Wall Street and corporate boardrooms, public health meetings and health centers to trace the ways sofosbuvir-based medicines became financial assets dominated by strategies of speculation and extraction at the expense of access and care. Provocative and sobering, this book illuminates the harmful impact of allowing financial markets to supersede democracy and human health and points to the necessary work of building more equitable futures"-- _cProvided by publisher. |
||
610 | 2 | 0 | _aGilead Sciences (Firm) |
650 | 0 |
_aDrug development _xEconomic aspects _zUnited States. |
|
650 | 0 |
_aDrugs _xPrices _zUnited States. |
|
650 | 0 |
_aHepatitis C _xTreatment _xPrices _zUnited States. |
|
650 | 0 |
_aPharmaceutical industry _xEconomic aspects _zUnited States. |
|
650 | 0 |
_aSofosbuvir _xPrices _zUnited States. |
|
776 | 0 | 8 |
_aRoy, Victor, 1986- _tCapitalizing a cure _dOakland, California : University of California Press, [2023] _z9780520388727 _w(DLC) 2022023733. |
776 | 0 | 8 | _iOnline version: |
999 |
_c523784 _d523784 |